- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy — Recruiting • Phase III • Oncology • NCT05774951.
- New hormone therapy drug tested against standard treatment in early breast cancer patients who've completed two years of initial hormone therapy.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months. Conditions: Breast Cancer, Early Breast Cancer Interventions: Camizestrant, Tamoxifen, Anastrozole, Letrozole, Exemestane Lead Sponsor: AstraZeneca Planned Enrollment:…